(0.31%) 5 115.91 points
(0.30%) 38 353 points
(0.37%) 15 986 points
(-0.95%) $83.05
(5.36%) $2.03
(0.33%) $2 355.00
(0.47%) $27.67
(4.15%) $960.35
(-0.27%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States...
Stats | |
---|---|
本日の出来高 | 64 126.00 |
平均出来高 | 229 541 |
時価総額 | 200.47M |
EPS | $-0.404 ( 2023-09-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.38 |
ATR14 | $0.270 (4.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-10 | Mcfarlane Neil F. | Buy | 600 000 | Stock Option (right to buy) |
2023-10-10 | Mcfarlane Neil F. | Buy | 200 000 | Restricted Stock Unit |
2023-10-10 | Mcfarlane Neil F. | Buy | 0 | |
2023-09-05 | Schafer Joshua | Buy | 500 | Common Stock |
2023-09-06 | Clifton R. Laduane | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
97.04 |
Last 89 transactions |
Buy: 4 356 177 | Sell: 72 592 |
ボリューム 相関
KemPharm Inc 相関
10 最も正の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
KemPharm Inc 相関 - 通貨/商品
KemPharm Inc 財務諸表
Annual | 2022 |
収益: | $10.46M |
総利益: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2022 |
収益: | $10.46M |
総利益: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2021 |
収益: | $28.65M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.15 |
FY | 2020 |
収益: | $13.29M |
総利益: | $11.98M (90.18 %) |
EPS: | $-3.21 |
Financial Reports:
No articles found.
KemPharm Inc
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。